Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
Overview
Orthopedia (KIDS) is a specialized medical device company dedicated exclusively to the field of pediatric orthopedics. Operating at the intersection of advanced medical technology and clinical expertise, the company designs, develops, and commercializes anatomically appropriate implants and surgical instruments. These innovative solutions are crafted to meet the distinct needs of pediatric patients, addressing conditions from long bone deformity correction and trauma management to spinal procedures and sports medicine. Keywords such as pediatric orthopedics, surgical implants, and clinical education reinforce the company’s technical focus from the very first introduction.
Core Business and Product Offering
At the heart of Orthopedia's operations lies a commitment to empowering pediatric orthopedic surgeons. The company’s product portfolio encompasses a range of state-of-the-art implants and instruments – each meticulously engineered to provide optimal treatment outcomes. Their offerings include specialized devices that aid in the correction of limb deformities, stabilization of fractures, and support for reconstructions, all designed with the care and precision that pediatric cases demand.
- Dedicated Research and Development: Orthopedia invests in continuous innovation, leveraging cutting-edge technology to refine implant design and improve surgical outcomes.
- Clinical and Educational Support: Beyond product development, the company emphasizes comprehensive clinical education and support programs that help surgeons stay updated on the latest procedures and applications.
- Comprehensive Product Range: From long bone deformity correction to trauma, spine care, and sports medicine, the company offers an integrated suite of solutions tailored for pediatric needs.
Market Position and Industry Significance
Orthopedia has positioned itself as a trusted name within the pediatric orthopedic market. With an unwavering focus on quality and innovation, the company has developed an expertise that ensures its products meet rigorous safety and efficacy standards. Its dedicated approach sets it apart from competitors who cover broader orthopedic applications, as Orthopedia champions solutions specifically designed for children. This clear specialization has cemented its role as a key industry resource for surgeons looking for products that reliably address pediatric orthopaedic conditions.
Operational Excellence and Expertise
The company’s operational framework is built upon a solid foundation of expert knowledge and technical prowess. By integrating engineering innovation with clinical insight, Orthopedia ensures that every implant and instrument is both practical in a surgical environment and tailored for the unique demands of pediatric physiology. The emphasis on quality, reliability, and educational support further demonstrates a commitment to elevating standard practices within the field. This multifaceted approach underlines the company’s role as not only a supplier of medical devices, but also as a partner in advancing pediatric orthopedic care globally.
Customer and Stakeholder Focus
Orthopedia’s offerings are crafted with the end-user in mind, primarily targeting healthcare institutions and pediatric orthopedic surgeons. The company’s comprehensive support system includes detailed training and ongoing clinical education, ensuring that surgeons are capable of utilizing these advanced tools to their fullest potential. Through its balanced approach to innovation and education, Orthopedia helps customers achieve better surgical outcomes and improved quality of life for pediatric patients.
Conclusion
In summary, Orthopedia (KIDS) exemplifies an unwavering focus on the niche field of pediatric orthopedics. The company combines advanced product engineering, dedicated clinical support, and a targeted market strategy to address the specialized needs of pediatric surgical care. By maintaining a consistent emphasis on quality and clinical expertise, Orthopedia continues to serve as a central resource for pediatric orthopedic solutions in the healthcare industry.
OrthoPediatrics (Nasdaq: KIDS) has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, marking their 80th system for treating pediatric musculoskeletal conditions. The system, recently FDA-cleared, is designed to treat Early Onset Scoliosis (EOS) in children under 10 years old who often experience pulmonary and digestive dysfunction.
The VerteGlide system aims to correct deformity while minimizing repeat surgeries until skeletal maturity. Initial surgeries are expected to begin at select children's centers during summer 2025. The technology was developed in partnership with pediatric orthopedic surgeons Dr. Richard McCarthy and Dr. Scott Luhmann, utilizing Shilla™ technology licensed from Medtronic.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's leadership team, including President & CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat during the conference.
Investors and interested parties can access the audio webcast of the discussion through OrthoPediatrics' investor relations website at http://ir.orthopediatrics.com, with a replay option available after the event.
OrthoPediatrics (Nasdaq: KIDS) has been named one of the 2025 Best Places to Work in Indiana for the 9th time by the Indiana Chamber of Commerce. The pediatric orthopedics-focused company joins 150 other organizations from over 20 industries across the state in this 20th edition of the recognition program.
Company President & CEO David Bailey emphasized their commitment to fostering an engaging and inclusive culture, highlighting continuous investments in employee development and meaningful career experiences. The recognition reflects the company's success in building a positive workplace environment focused on helping children.
Indiana Chamber President Vanessa Green Sinders noted the program's importance in evaluating workplace culture amid intense talent competition. The final rankings will be revealed at an awards ceremony on April 30th, 2025, followed by publication in the Chamber's BizVoice® magazine.
OrthoPediatrics (Nasdaq: KIDS) has announced its partnership with the Crossroads Pediatric Device Consortium (CPDC), a multi-institutional initiative focused on accelerating pediatric medical device development. The consortium includes Purdue University's Weldon School of Biomedical Engineering, the Indiana University School of Medicine's Department of Pediatrics, and Cook Medical.
This collaboration aims to strengthen the consortium's capabilities in developing and commercializing pediatric medical devices, particularly in orthopedics. The partnership leverages OrthoPediatrics' specialized expertise in pediatric orthopedics to enhance the consortium's innovative potential.
The CPDC's distinctive model integrates major medical device companies to streamline product development, regulatory navigation, and commercialization processes, ensuring efficient transition of pediatric medical innovations from concept to market.
OrthoPediatrics (NASDAQ: KIDS) reported strong financial results for Q4 and full year 2024. The company achieved record annual revenue of $204.7 million, up 38% from 2023, with domestic revenue increasing 45% and international revenue growing 15%.
Q4 2024 highlights include total revenue of $52.7 million, a 40% increase year-over-year, and adjusted EBITDA of $3.0 million, more than double compared to Q4 2023. The company helped over 34,000 children in Q4 and approximately 138,000 for the full year.
Key segment performance for 2024:
- Trauma and Deformity revenue: $145.1 million (+36%)
- Scoliosis revenue: $55.2 million (+45%)
- Sports Medicine/Other: $4.4 million (+11%)
For 2025, OrthoPediatrics projects revenue between $235.0-242.0 million, representing 15-18% growth, and expects adjusted EBITDA of $15.0-17.0 million.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
Investors can access the conference call through a live and archived webcast available on the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast will remain available for replay for at least 90 days following the event.
OrthoPediatrics Corp. (NASDAQ: KIDS) has announced a distribution agreement with Thrive Orthopedics through its OrthoPediatrics Specialty Bracing (OPSB) division. The agreement covers three pediatric orthotic solutions:
1. The F3 Hero Pediatric AFO: A carbon fiber ankle foot orthosis for children with walking challenges due to cerebral palsy, spina bifida, or chemotherapy-related foot drop.
2. The TruStretch Pediatric Equinus Brace®: An above-the-knee brace for stretching gastroc-soleus muscles in children with equinus deformity.
3. The Thrive® Pediatric X-Glide Carbon Fiber Insoles: Available in rigid and flexible styles as lightweight gait training tools.
OrthoPediatrics (NASDAQ: KIDS) announced record preliminary unaudited revenue for 2024, reaching $204.7 million, a 38% increase from 2023's $148.7 million. The company's domestic revenue grew 45% to $161.1 million, while international revenue increased 16% to $43.6 million.
Fourth quarter 2024 revenue reached $52.7 million, up 40% year-over-year, with domestic revenue growing 52% to $42.9 million and international revenue rising 5% to $9.8 million. The company helped over 34,000 children in Q4 2024, surpassing 1.1 million children helped since inception.
For 2025, OrthoPediatrics projects revenue between $235-242 million (15-18% growth), with expected annual set deployment of $15 million and adjusted EBITDA of $15-17 million. The company highlighted strong performance in Trauma and Deformity, Scoliosis, and specialty bracing businesses.
OrthoPediatrics Corp. (KIDS) announced the expansion of its Specialty Bracing (OPSB) division into three new markets in Indiana, Colorado, and Florida. The OPSB division, launched in early 2024, aims to increase pediatric care access through new clinics and strategic acquisitions.
The company opened a new clinic in Indianapolis near Riley Children's Hospital and Peyton Manning Children's Hospital, established a new site within Nationwide Children's Hospital in Columbus, OH, acquired a clinic group in Colorado with plans for Denver area expansion, and acquired a clinic in Davie, Florida, serving as a foundation for statewide growth.
This expansion is part of OPSB's multi-year strategy to enhance access to non-operative pediatric orthopedic solutions through both greenfield clinics and strategic acquisitions, focusing on partnerships with pediatric orthopedic surgeons across different regions.
OrthoPediatrics Corp. (Nasdaq: KIDS) has expanded its Specialty Bracing portfolio with two new products: the OPSB Sensor System and MOVE-D™. The OPSB Sensor System is the company's first sensor solution, featuring Bluetooth connectivity that uploads wear-time data to an interactive app with gamification elements and cloud-based storage for healthcare provider monitoring. The MOVE-D™, acquired through license and distribution agreements with Innovation Lab, is a mechanical elbow brace designed to stabilize tremors in the dominant upper extremity for pediatric patients with movement disorders, improving daily activities performance.
The company's subsidiary, Boston Orthotics & Prosthetics, has been using thermal sensors in scoliosis braces for over 10 years, based on research showing correlation between brace wear time and treatment success.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
What is Orthopedia's core business?
How does Orthopedia differentiate itself from other orthopedic companies?
What types of products does Orthopedia offer?
Who are the primary customers of Orthopedia?
How does Orthopedia support clinical education?
What is the significance of technology and innovation for Orthopedia?
How does Orthopedia ensure product quality?
